FOXF1 and lung adenocarcinoma: Next, we searched for the presence of promoter hypermethylation by MSP analysis at FOXF1 in 10 lung adenocarcinoma samples and their adjacent normal tissues (Supplementary Figure 4), aberrant promoter hypermethylation was detected in 2 of 10 lung adenocarcinoma patients (2/10, 20%).